Source link : https://www.newshealth.biz/health-news/intravitreal-implant-could-transform-wet-amd-treatment/
An intravitreal implant (OTX-TKI) containing the tyrosine kinase inhibitor axitinib (Inlyta) was well tolerated and significantly reduced injection frequency by nearly 90% in patients with wet age-related macular degeneration (AMD), according to results from a phase I study presented at the American Academy of Ophthalmology meeting. In this exclusive MedPage Today video, David Eichenbaum, MD, […]
Author : News Health
Publish date : 2024-11-07 19:13:00
Copyright for syndicated content belongs to the linked Source.